|
[1]
|
Nagasaka, M. and Gadgeel, S.M. (2018) Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. Expert Review of Anticancer Therapy, 18, 63-70.
[Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Pirker, R. (2020) Chemotherapy Remains a Cornerstone in the Treatment of Nonsmall Cell Lung Cancer. Current Opinion in Oncology, 32, 63-67.
[Google Scholar] [CrossRef]
|
|
[3]
|
Imyanitov, E.N., Iyevleva, A.G. and Levchenko, E.V. (2021) Molecular Testing and Targeted Therapy for Non-Small Cell Lung Cancer: Current Status and Perspectives. Critical Reviews in Oncology/Hematology, 157, Article ID: 103194.
[Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Reck, M. and Gatzemeier, U. (2004) Chemotherapy in Stage-IV NSCLC. Lung Cancer, 45, S217-S222.
[Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Klastersky, J. and Awada, A. (2012) Milestones in the Use of Chemotherapy for the Management of Non-Small Cell Lung Cancer (NSCLC). Critical Reviews in Oncology/Hematology, 81, 49-57.
[Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Lemjabbar-Alaoui, H., Hassan, O.U., Yang, Y.-W. and Buchanan, P. (2015) Lung Cancer: Biology and Treatment Options. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1856, 189-210.
[Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Moreira, A.L. and Eng, J. (2014) Personalized Therapy for Lung Cancer. CHEST, 146, 1649-1657.
[Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Fang, B., Mehran, R.J., Heymach, J.V. and Swisher, S.G. (2015) Predictive Biomarkers in Precision Medicine and Drug Development against Lung Cancer. Chinese Journal of Cancer, 34, Article No. 26.
[Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Yang, H., Jiang, P., Liu, D., et al. (2019) Matrix Metalloproteinase 11 Is a Potential Therapeutic Target in Lung Adenocarcinoma. Molecular Therapy-Oncolytics, 14, 82-93.
[Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Liu, S.V., Subramaniam, D., Cyriac, G.C., Abdul-Khalek, F.J. and Giaccone, G. (2014) Emerging Protein Kinase Inhibitors for Non-Small Cell Lung Cancer. Expert Opinion on Emerging Drugs, 19, 51-65.
[Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Dempke, W.C., Suto, T. and Reck, M. (2010) Targeted Therapies for Non-Small Cell Lung Cancer. Lung Cancer, 67, 257-274.
[Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Liu, X., Newton, R.C. and Scherle, P.A. (2011) Development of c-MET Pathway Inhibitors. Expert Opinion on Investigational Drugs, 20, 1225-1241.
[Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Rolfo, C., Ruiz, R., Giovannetti, E., et al. (2015) Entrectinib: A Potent New TRK, ROS1, and ALK Inhibitor. Expert Opinion on Investigational Drugs, 24, 1493-1500.
[Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Mazieres, J., Barlesi, F., Filleron, T., et al. (2016) Lung Cancer Patients with HER2 Mutations Treated with Chemotherapy and HER2-Targeted Drugs: Results from the European EUHER2 Cohort. Annals of Oncology, 27, 281-286.
[Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Liu, D., Vokes, N.I. and Van Allen, E.M. (2017) Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. Cancer Discovery, 7, 555-557.
[Google Scholar] [CrossRef]
|
|
[16]
|
Tiseo, M., Loprevite, M. and Ardizzoni, A. (2004) Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer. Current Medicinal Chemistry-Anti-Cancer Agents, 4, 139-148.
[Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Cabebe, E. and Wakelee, H. (2007) Role of Anti-Angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors. Current Treatment Options in Oncology, 8, 15-27.
[Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Yagui-Beltrán, A., He, B., Raz, D., Kim, J. and Jablons, D.M. (2006) Novel Therapies Targeting Signaling Pathways in Lung Cancer. Thoracic Surgery Clinics, 16, 379-396.
[Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Wu, D., Wang, D.C., Cheng, Y., et al. (2017) Roles of Tumor Heterogeneity in the Development of Drug Resistance: A Call for Precision Therapy. Seminars in Cancer Biology, 42, 13-19.
[Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Sacco, J.J., Al-Akhrass, H. and Wilson, C.M. (2016) Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer. Current Pharmaceutical Design, 22, 4374-4385.
[Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Lizardi, P.M., Forloni, M. and Wajapeyee, N. (2011) Genome-Wide Approaches for Cancer Gene Discovery. Trends in Biotechnology, 29, 558-568.
[Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Lee, E. and Moon, A. (2016) Identification of Biomarkers for Breast Cancer Using Databases. Journal of Cancer Prevention, 21, 235-242.
[Google Scholar] [CrossRef]
|
|
[23]
|
Bassiouni, W., Ali, M. A. and Schulz, R. (2021) Multifunctional Intracellular Matrix Metalloproteinases: Implications in Disease. The FEBS Journal, 288, 7162-7182.
[Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Murphy, G. and Nagase, H. (2008) Progress in Matrix Metalloproteinase Research. Molecular Aspects of Medicine, 29, 290-308.
[Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Quintero-Fabián, S., Arreola, R., Becerril-Villanueva, E., et al. (2019) Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Frontiers in Oncology, 9, Article 1370.
[Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Zhang, X., Huang, S., Guo, J., et al. (2016) Insights into the Distinct Roles of MMP-11 in Tumor Biology and Future Therapeutics. International Journal of Oncology, 48, 1783-1793.
[Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Wang, Y., Wei, Y., Fan, X., et al. (2020) MicroRNA-125b as a Tumor Suppressor by Targeting MMP11 in Breast Cancer. Thoracic Cancer, 11, 1613-1620.
[Google Scholar] [CrossRef] [PubMed]
|